氯贝丁酯与考来烯胺单独及联合应用对Ⅲ型高脂蛋白血症患者血脂及脂蛋白的影响。
Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
作者信息
Hoogwerf B J, Peters J R, Frantz I D, Hunninghake D B
出版信息
Metabolism. 1985 Oct;34(10):978-81. doi: 10.1016/0026-0495(85)90149-0.
The effects of colestipol, clofibrate, and a combination of these two drugs on plasma lipid and lipoprotein values were evaluated in seven subjects with type III hyperlipoproteinemia. When compared to baseline, colestipol administration resulted in a significant decrease in LDL-cholesterol (146 v 99, P less than 0.01) and a significant increase in VLDL-triglycerides (260 v 399, P less than 0.05). The increases in total triglycerides (346 v 462, P = 0.09) and VLDL-C (117 v 155, P = 0.17) noted with colestipol were not statistically significant. Clofibrate administration increased HDL-C (37 v 46, P less than 0.05), and lowered VLDL-C (117 v 56, P less than 0.05), VLDL-triglycerides (260 v 144, P less than 0.05) and total triglycerides (346 v 218, P less than 0.01). The combined regimen was more effective than clofibrate in lowering total and LDL-cholesterol, and no other significant differences were noted.
在7名III型高脂蛋白血症患者中评估了考来替泊、氯贝丁酯以及这两种药物联合使用对血浆脂质和脂蛋白值的影响。与基线相比，服用考来替泊导致低密度脂蛋白胆固醇显著降低（146对99，P<0.01），极低密度脂蛋白甘油三酯显著升高（260对399，P<0.05）。考来替泊使总甘油三酯（346对462，P=0.09）和极低密度脂蛋白胆固醇（117对155，P=0.17）升高，但无统计学意义。服用氯贝丁酯使高密度脂蛋白胆固醇升高（37对46，P<0.05），并降低了极低密度脂蛋白胆固醇（117对56，P<0.05）、极低密度脂蛋白甘油三酯（260对144，P<0.05）和总甘油三酯（346对218，P<0.01）。联合用药方案在降低总胆固醇和低密度脂蛋白胆固醇方面比氯贝丁酯更有效，未发现其他显著差异。
Zotero 插件